BioNTech stock price hovers at $91.09, with short-term trend lines indicating consolidation before a likely breakout pattern. Investor focus is partly on macro vaccine deployment trends influencing quarterly cash flows. We have already established that ROE serves as an efficient profit-generating gauge for a company's future earnings. Based on how much of its profits the company chooses to reinvest or "retain", we are then able to evaluate a company's future ability to generate profits. Assuming all else is equal, companies that have both a higher return on equity and higher profit retention are usually the ones that have a higher growth rate when compared to companies that don't have the same features. Moderna took another step to cut costs Thursday as it announced it will slash roughly 10% of its workforce by the end of the year. BioNTech stock price is at $90.98, reacting mildly to sector-wide news of R&D tax incentives in Europe. Analysts note that policy shifts could alter forward P/E estimates for biotech players.
